Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2012. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding changes in their interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider trading activity rather than a financial performance report.
Material Changes
The material change reported is the acquisition of Ordinary Shares by five individuals on August 6, 2012. These purchases were executed at a price of 1,498.517 pence per share and resulted from the re-investment of dividends on shares held within Individual Savings Accounts (ISAs). The specific share counts acquired were:
- Sir Andrew Witty: 37 shares
- Mr S M Bicknell: 81 shares
- Mr E J Gray: 7 shares
- Mr D S Redfern: 16 shares
- Mrs V A Whyte: 14 shares
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The transaction was notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of 1,498.517 pence per Ordinary Share on August 6, 2012.
- Confirm the total number of shares held by the listed directors following these dividend re-investments.
- Note that this filing does not reflect the company's operational or financial performance for the period.